Swiss-Origin Generic Drug Tariffs Lifted: What Importers Need to Know
Table of Contents
A recent U.S. government decision is offering potential refunds to importers of Swiss-made generic pharmaceuticals, reversing tariffs imposed earlier in 2025.
- The U.S. removed reciprocal tariffs on Swiss generic drugs and ingredients, effective retroactively to Nov. 14, 2025.
- Importers who paid duties since Nov. 14, 2025, may be eligible for refunds.
- Companies should review import records and prepare documentation to claim these refunds.
- Transfer pricing and customs valuation adjustments may be necessary.
Earlier in 2025, the United States implemented reciprocal tariffs on specific Swiss goods, including generic pharmaceuticals, as part of ongoing trade discussions. However, on Dec. 18, 2025, the U.S. government announced the removal of these tariffs on Swiss-origin generic pharmaceuticals and their ingredients via a notice published in the Federal Register. This change, effective retroactively to Nov. 14, 2025, is a result of a new trade agreement with Switzerland and Liechtenstein, designed to foster fair trade and ensure continued access to essential medical supplies.
What does this mean for importers? Importers who paid duties on covered products since Nov. 14, 2025, may now qualify for refunds. The tariff relief specifically applies to generic pharmaceuticals and their ingredients manufactured in Switzerland. This development could reduce costs for importers and distributors, potentially stabilizing supply chains and improving profitability.
Securing Your Refund: A Step-by-Step Guide
To take advantage of this tariff relief, importers should promptly review their records and prepare the necessary documentation for refund claims. Here’s a breakdown of the key steps:
- Identify Eligible Entries: Scrutinize import records to pinpoint entries of Swiss-origin generic pharmaceuticals and ingredients imported on or after Nov. 14, 2025, that were subject to the reciprocal tariff.
- Prepare Documentation: Assemble supporting documents, including commercial invoices, bills of lading, entry summaries, and proof of Swiss origin and product classification as a generic pharmaceutical or ingredient.
- Coordinate with Customs Brokers: Collaborate with your customs broker to prepare and submit post-summary corrections (PSCs) to U.S. Customs and Border Protection (CBP), clearly referencing the Federal Register notice and providing all required documentation to support the claim for tariff relief.
- Monitor Refund Processing: Track the status of refund claims and maintain open communication with your customs broker and CBP to ensure timely processing and resolution.
The Interplay of Transfer Pricing and Customs Valuation
For companies with global operations, this tariff change intersects with transfer pricing and customs valuation. If your company’s transfer pricing policy was impacted by the tariffs, ensure any adjustments to intercompany pricing are accurately reflected in both your customs and tax filings.
U.S. Customs and Border Protection (CBP) permits retroactive adjustments to customs value if an objective formula was established before importation and the adjustment mechanism was in place at the time of entry. Proper documentation and alignment with section 482 transfer pricing policies are crucial for compliance and refund eligibility.
Expert Consultation is Key
Given the complex relationship between customs, tax, and transfer pricing, consulting with your tax and trade advisors is highly recommended. This will ensure all aspects of the refund process are addressed and potential compliance risks are mitigated. Prompt action is essential to identify eligible entries, gather documentation, and coordinate with customs brokers for timely refund claims.
